Avamed Synergy advances Fluxus in Alicante and beyond
Avamed Synergy, led by Lucas Diez as chief executive and founder, operates from the Distrito Digital technology hub in Alicante. The company reported that 800,000 euros have been secured in the first stage of its investment round for Flux, according to the company itself.
Founded in 2010, Avamed Synergy is a technology transfer firm focused on the healthcare sector. The capital increase required for this round has been formalized, and the round remains open with a target to close in the first quarter of 2024 if the company reaches its planned milestones. Achieving this budget would enable the execution of a strategic plan aimed at establishing a leadership position in precision medicine and medical imaging.
Fluxus projects enable clinical study sessions with a unique host-tumor interface through artificial intelligence and local algorithms. They assess tumor type and subtype, aggressiveness, evolution, and, ultimately, the most suitable treatment path for each patient. The tool has already undergone prior clinical studies and is currently in a pilot and evaluation phase. If results remain favorable, Fluxus could support regulatory approval for marketing.
The group of investors backing Fluxus, including veterans of venture capital, contributed 500,000 euros in this round. ENISA also contributed to bring the total to 800,000 euros for this initial phase. In 2024, Avamed Synergy intends to welcome additional investors and funding vehicles interested in advancing this project.
Innovation in surgical services
The milestone positions the company to grow its research team and continue pursuing the health certifications necessary to enter the European healthcare market.
Diez expresses strong confidence in Fluxus as a catalyst for transformation in complex surgeries. He notes that Fluxus places Avamed Synergy at the forefront of technology and digital health innovation in oncology. Through sustained investment in research and development and active participation in the medical community, the company aims to make a meaningful difference for patients and to contribute to the broader shift toward personalized medicine.
[Source: Avamed Synergy press materials]